- Home
- NFE vs SCTX Comparison
NFE vs SCTX Comparison
Compare NFE & SCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NFE | SCTX |
|---|---|---|
| Founded | 2014 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil/Gas Transmission | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 324.4M | 330.1M |
| IPO Year | 2018 | 2026 |
Fundamental Metrics
Financial Performance| Metric | NFE | SCTX |
|---|---|---|
| Price | $0.29 | $31.21 |
| Analyst Decision | Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $5.50 | N/A |
| AVG Volume (30 Days) | ★ 1.8M | 223.3K |
| Earning Date | 04-13-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,504,037,000.00 | N/A |
| Revenue This Year | $110.34 | N/A |
| Revenue Next Year | $3.54 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.25 | $17.31 |
| 52 Week High | $3.08 | $39.60 |
Technical Indicators
Market Signals| Indicator | NFE | SCTX |
|---|---|---|
| Relative Strength Index (RSI) | 33.69 | 75.78 |
| Support Level | N/A | $19.09 |
| Resistance Level | $0.37 | $39.60 |
| Average True Range (ATR) | 0.02 | 3.56 |
| MACD | -0.00 | 1.59 |
| Stochastic Oscillator | 27.97 | 87.23 |
Price Performance
Historical ComparisonAbout NFE New Fortress Energy Inc.
New Fortress Energy Inc is an integrated gas-to-power company. Its business model spans the entire production and delivery chain from natural gas procurement and liquefaction to logistics, shipping, terminals, and conversion or development of a natural gas-fired generation. It has invested in floating, liquefied natural gas vessels to lower the cost of acquiring gas while securing a long-term supply for its terminals. Its segments include Terminals & Infrastructure, and Ships. It generates the majority of its revenue from the Terminals & Infrastructure segment.
About SCTX Scribe Therapeutics Inc. Common Stock
Scribe Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of in vivo CRISPR-based genetic medicines. Its research and development activities focus on cardiovascular and metabolic diseases, including atherosclerotic cardiovascular disease (ASCVD). The company's product pipeline includes STX-1150, a CRISPR-based product candidate that utilizes its ELXR epigenetic silencing technology.